ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (D...( ADDISON Texas March 18 /- ULURU Inc. ...),Health

ADDISON, Texas, March 18 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) announced that clinical evidence on the treatment of diabetic foot ulcers, and data on the use of its patented Nanoflex(TM) Technology for Therapeutic Delivery will be presented at the annual DFCon Global Meeting in Los Angeles, California March 19-21. The work will be presented on posters that will be on display during the meeting.

Clinical evidence will be presented on a poster titled, "Nanoparticulate Aggregate Wound Dressing in the Management of Soft Tissue Wounds". This research details the application of Altrazeal(TM) in the treatment of a patient following radical debridement of necrotizing fasciitis. Commenting on the work, DFCon organizer and one of the study's co-authors, Dr. David Armstrong, Professor of Surgery and Director, Southern Arizona Limb Salvage Alliance (SALSA) University of Arizona College of Medicine stated, "We have been provisionally impressed with this modality. We believe that marrying such technologies with an aggressive team effort might well prove helpful in reducing the unnecessarily high rate of amputations in the USA and worldwide."

Further clinical evidence for the use of Altrazeal(TM) in treating diabetic foot ulcers is detailed in a poster titled "Properties of a Novel Powder Wound Dressing and Clinical Experience in Diabetic Foot Ulcers." This work presents the use of Altrazeal(TM) Transforming Powder Dressing in the treatment of four separate ulcers in diabetic patients. The treatments were performed by Gregory Bohn, MD FACS, the Medical Director of Trinity Center for Wound Care and Hyperbaric Medicine in Bettendorf, IA., Sid Sharma, DPM FAPWCA, and Gianni Persich, DPM FAPWCA both at All Country Podiatry in NY. Four cases of ulcers present on heel, to
'/>"/>